Open AccessEmerging data on the treatment of multiple sclerosis
Author(s) -
Andrei Ciuhan,
AUTHOR_ID,
Lăcrămioara PerjuDumbravă,
Nicoleta Tohănean,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2021
Publication title -
romanian journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 4
eISSN - 2069-6094
pISSN - 1843-8148
DOI - 10.37897/rjn.2021.3.2
Subject(s) - medicine , alemtuzumab , cladribine , ofatumumab , medical physics , frequentist inference , medline , cochrane library , natalizumab , multiple sclerosis , meta analysis , bayesian probability , computer science , artificial intelligence , rituximab , bayesian inference , psychiatry , transplantation , lymphoma , political science , law
Background and objectives. In the past few years, a myriad of new studies were aimed to find better ways to manage MS. As a result, a bunch of new molecules were found to have good efficacy, therefore FDA and EMA approved a series of treatments in the last few years, the last one receiving green light from EMA on March 30th, 2021 (Ofatumumab – Kesimpta®). The aim of this study was to evaluate and classify three of the newest drugs approved by the FDA and EMA. Material and methods. All the studies were chosen on the basis of pre-determined inclusion criteria and in accordance with PRISMA guidelines. We searched Pubmed and Cochrane Library for all studies published up until the end of 2020. For the data analysis we used MetaInsight®, a statistical web-based tool for meta-analyses and NMAs performing both Frequentist and Bayesian hierarchical model analyses, each one being seen as a sensitivity check for the other. Outcomes. The best therapeutic agent in reported efficacy amongst the three analyzed was Ofatumumab, ranked first in hierarchy, Ozanimod and Cladribine following in the second and third place, respectively. Conclusions. According to ABN’s 2015 guidelines, Cladribine was ranked between the most effective medicines for the treatment of MS; given the results from this study, other two may be considered as high efficacy alongside Natalizumab, Alemtuzumab and Ocrelizumab.